Results from the ADVANCE-1 phase 2/3 trial suggest that a novel treatment may reduce agitation associated with Alzheimer’s disease (AD).
The treatment, known as AXS-05, is a dextromethorphan/bupropion oral tablet with multimodal effects on several neurotransmitter systems implicated in the cognitive and behavioral abnormalities associated with AD.
Agitation is reported in up to 70% of patients with AD. It is associated with accelerated cognitive decline, increased caregiver burden, early institutionalization, and increased mortality. Despite its negative impact, there is currently no approved treatment for AD agitation.
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.